human gut has been recognized as an important risk factor for the development of obesity-related diseases, including hypertension and T2DM. [6] [7] [8] During the past two decades, accumulative evidence has demonstrated that enteric bacterial products (eg lipopolysaccharides [LPS] ) could cross the impaired intestinal barrier to reach peripheral circulation and contributed to the low-grade chronic inflammatory state. 9, 10 More recently, the results from several studies have suggested that both serum LPS and LPS-binding protein levels were closely associated with obesity, metabolic syndromes, T2DM, and T2DM-associated arterial stiffness, [11] [12] [13] indicating that impaired intestinal barrier plays an etiology role in these chronic diseases development.
Blood in healthy humans is generally considered as a "sterile" environment. However, a number of sequence-based and ultramicroscopic studies have reported that the gut microbiota could translocate into blood due to increased intestinal permeability. [14] [15] [16] [17] In a recent study on a large general population, Amar et al 18 observed that blood microbiota dysbiosis was significantly associated with the onset of cardiovascular events. Although more and more studies have suggested the presence of apparent associations between gut microbiome or enteric bacterial products and the onset of T2DM, there is a lack of information on the role of blood microbiome in T2DM development. Therefore, in the present study nested in a "135" cohort in the Chinese city of Soochow, we directly assessed the microbiome in blood by high-throughput sequencing of the 16S ribosomal RNA (16S rRNA) gene using pre-diagnostic blood samples collected from T2DM cases and controls and compared two groups for baseline overall blood microbiome composition and relative abundance of specific bacterial taxa.
| ME THODS

| Study participants
The participants included in the present study were nested in a "135" cohort study, which is an ongoing prospective study and aims to investigate risk factors for chronic diseases including diabetes mellitus.
Details on the methodology of the "135" study have been described before. 19 In brief, total 5782 adults, aged from 35-70 years, were recruited between March 2013 and September 2013 from Soochow, China. The demographic characteristics of each participant including weight, height, and blood pressure were collected by face-to-face interview. The first round follow-up survey was conducted in 2015.
T2DM cases were defined as incident cases (for those with no previous history of diabetes and had never used diabetic medication at the time of the baseline survey), and a diagnosis of T2DM was confirmed by a physician, or the reported use of T2DM medication at the time of the follow-up survey.
In the present nested case-control study, 100 controls were matched to 50 T2DM cases with sex and age (5 years). Pregnant women and individuals with cancers, chronic viral hepatitis, renal failure, chronic enteritis, and diarrhea were excluded. Additionally, no subject (in both T2DM and control groups) had taken antibiotic, probiotic, or prebiotic products since two months before the sample collection. This study received approval from the Ethics Committee of SIPCDC (Suzhou Industrial Park Centers for Disease Control and Prevention) in accordance with the 1975 Declaration of Helsinki.
Informed consent was obtained from all individual participants.
| Sample collection and laboratory measurement
Blood samples were taken by venipuncture after at least 8-hour overnight fast. Tubes were centrifuged at 3000 g for 10 minutes at room temperature for separation. Plasma samples were frozen at −80°C for storage as quickly as possible. Fasting plasma glucose (FPG), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were measured using an autoanalyzer (Olympus AU640, Tokyo, Japan). 
| DNA extraction, 16S rRNA gene amplification, and sequencing
| Derivation of microbiome data and quality controls
Sequence reads processing was performed using QIIME (Quantitative Insights Into Microbial Ecology, QIIME: http://qiime.org/) package 
| Statistical analysis
Statistical analyses were performed using SAS 9.4 software (SAS Institute, Cary, NC, USA). Independent t tests and Mann-Whitney U test were applied for continuous variables. For categorical variables between groups, we used either the Pearson chi-square or
Fisher's exact test. In order to analyze the associations between bacteria taxa and T2DM risk, subjects were categorized into two groups as carriers and non-carriers of the pathogens because of low relative abundance of most pathogens in blood. The non-carrier meant that the individual did not have sequence read for the specific pathogen. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CIs) for measuring the association of specific blood pathogen with T2DM risk. Potential confounder factors including BMI, blood pressure, smoking, drinking, TC, and TG were adjusted. In the present study, we limited our analysis of bacterial phyla to those with mean relative abundance ≥0.01%. For lower level taxa (class to genus), we limited analysis to those with mean relative abundance ≥0.0001%. All tests of significance were two-sided, and P < 0.05 was considered statistically significant.
| RE SULTS
| Characteristics of the studied population
Demographic characteristics of cases (participants who developed T2DM) and controls (participants who did not develop T2DM) are shown in Table 1 . T2DM cases and non-T2DM controls in the present study were similar with respect to the matching factors of age and gender. In addition, smoking, drinking, baseline FPG did not significantly differ between cases and controls. However, participants who developed T2DM were more likely to be with hypertension, increased levels of TC, TG, and LDL at baseline. As expected, the plasma level of HDL in control group was apparently lower than that in T2DM group at baseline.
| Sequencing data summarization
The total number of reads obtained from 150 participants was 9 968 238. After filtering and removing the chimeric sequences, we obtained 3 000 391 high-quality sequences from the partici- (Table S1) .
As the results shown in different between the T2DM cases and non-T2DM controls at baseline. 
| Associations of microbiome composition with diabetes
According to the limited criteria described in the "materials and methods," four phyla, 14 classes, 37 orders, 97 families, and 196 genera were included for further analysis in the present study. The results showed that no significant difference in relative abundance of bacterium was detected between two groups at phylum level. were much higher in T2DM cases than those in non-T2DM controls (Table S1-S5, Table 5 ).
TA B L E 4 Richness and diversity estimators in different groups
Because of low relative abundance of most pathogens in blood, we further examined the associations of blood microbiome with the onset of T2DM by characterizing the participants as carriers and non-carriers of the pathogens. As the results shown in (Table 6 ).
However, the results from FDR correction indicated that no significant association was detected between blood microbiome and T2DM development (Table S5 ).
| D ISCUSS I ON
Recently, an increasing number of studies have reported that human blood contains an authentic microbiome. 18, [20] [21] [22] In the present study, our data showed that the peripheral blood collected from both cases and controls has a diverse bacterial microbiota, dominated by the phyla Proteobacteria, Bacteroidetes, Firmicutes,
and Actinobacteria. This result is somewhat similar to the findings reported by previous studies. The results from a France study observed that the peripheral blood from healthy donors contains bacterial DNA mostly from the Proteobacteria phylum (between 80.4% and 87.4%), Actinobacteria phylum (between 6.7% and 10.0%), the Firmicutes (between 3.0% and 6.4%), and Bacteroidetes (between 2.5% and 3.4%) phyla. 16 To date, whether a diverse bacterial community is present in the blood of T2DM patients remains unclear. Larsen et al 23 Bacteroidetes (F/B) (the relative abundance in gut) was much higher in the patients with T2DM. 23 However, our present data did not observe that the composition of blood microbiome in T2DM patients is different with those in non-T2DM control at phyla level. Moreover, there was no significant difference in the value of F/B between T2DM participants and non-T2DM controls (data not shown). It is well known that the blood microbiome is derived primarily from the gut microbiome as a result of bacterial translocation. [24] [25] [26] [27] However, as previously reported, the blood and gut microbiomes differ significantly from each other, indicating that the intestinal barrier, immune cells, and liver might play a role of filtering and affecting the bacterial translocation. [28] [29] [30] [31] [32] These results could partially explain the difference of the bacterial community diversity between the gut and blood. To our knowledge, this is the first nested case-control study to explore the role of blood microbiome in the development of T2DM.
However, our present study did contain some limitations. First, we can only analyze the bacteria at the genus level in relation to T2DM risk. Whole metagenome shotgun sequencing is required for a further exploration of the microbiome at the species/strain level. Second, the information about antibiotics treatment during past six months in studied population was not collected. We cannot judge longitudinal effects of antibiotics on the blood bacterial community. Last, most of the bacterial taxa in our blood samples had a low prevalence and abundance, and our study did not have sufficient power to carry out a systematic evaluation of this. Additionally, because the results from FDR correction showed that no significant association was detected between blood microbiome and T2DM development, more investigation with a large sample size is needed in future.
| CON CLUS IONS
In conclusion, our results suggested that blood microbiome may play an etiology role in the development of T2DM. In future, larger follow-up studies are warranted in order to further determine the relationships between blood microbiome and the risk of T2DM.
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